Fig. 5 | Genetics in Medicine

Fig. 5

From: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review

Fig. 5

Flow diagram showing the derivation of clinical sensitivity and specificity of UGT1A1 genotyping to identify severe neutropenia in a hypothetical cohort of 20,000 white individuals with metastatic colorectal cancer. The clinical sensitivity and specificity are derived using previously reported parameters (e.g., allele frequency, risk ratios), stratified by UGT1A1 genotype. Overall, the clinical sensitivity is 24% with a specificity of 91% (false positive rate of 9%).

Back to article page